摘要
背景:很少有正常脑脊液(CSF)生物标志物谱的患者符合阿尔茨海默病(AD)的临床标准。 目的:本研究的目的是检验这些患者误诊的假设。 方法:来自e-PLM中心的患者满足由于AD(AD-MCI)引起的可能的AD痴呆或轻度认知障碍的核心临床标准,具有正常的CSFAβ1-42,T-tau和P-tau生物标志物以及临床随访包括在内。临床和影像学资料由独立委员会从基线(访问临床评估和CSF分析)到随访结束时进行复查,以作最终诊断。 结果:在1098例AD患者的脑脊液分析的e-PLM队列中,37例(3.3%)患者(20例AD痴呆核心临床标准,17例AD-MCI核心临床标准)脑脊液生物标志物谱正常,向上。所有患者均出现情景记忆障碍,27例(73%)患者在MRI扫描时出现内侧颞叶萎缩。中位随访36个月(范围7-74)后,最终诊断为AD MCI或9例(24%)患者的痴呆,并且由于28例(76%)患者的AD而不太可能。 18例(49%)患者(情绪障碍,非AD退行性痴呆,血管性认知功能障碍,酒精认知障碍,颞叶癫痫和海马硬化)纠正了误诊,10例(27%)患者的认知障碍未确定 结论:具有正常脑脊液生物标志物的AD诊断(MCI或痴呆)是一种罕见的病症。 特别建议临床随访考虑替代诊断。
关键词: 阿尔茨海默病,痴呆,轻度认知障碍,生物标志物,脑脊液,血管性痴呆,额颞叶痴呆,抑郁症。
Current Alzheimer Research
Title:Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Volume: 15 Issue: 7
关键词: 阿尔茨海默病,痴呆,轻度认知障碍,生物标志物,脑脊液,血管性痴呆,额颞叶痴呆,抑郁症。
摘要: Background: Few patients with a normal cerebrospinal fluid (CSF) biomarker profile fulfill the clinical criteria for Alzheimer disease (AD).
Objective: The aim of this study was to test the hypothesis of misdiagnoses for these patients.
Method: Patients from the e-PLM centers fulfilling the core clinical criteria for probable AD dementia or mild cognitive impairment due to AD (AD-MCI), with normal CSF Aβ1-42, T-tau and P-tau biomarkers and clinical follow-up, were included. Clinical and imaging data were reviewed by an independent board, from baseline (visit with clinical evaluation and CSF analysis) to the end of the follow-up, for a final diagnosis.
Results: In the e-PLM cohort of 1098 AD patients with CSF analysis, 37 (3.3%) patients (20 with AD dementia core clinical criteria and 17 with AD-MCI core clinical criteria) had normal CSF biomarker profile and a clinical follow-up. All patients presented with episodic memory impairment and 27 (73%) had medial temporal lobe atrophy on MRI-scan. After a median follow-up of 36 months (range 7-74), the final diagnosis was AD MCI or dementia for 9 (24%) patients, and unlikely due to AD for 28 (76%) patients. A misdiagnosis was corrected in 18 (49%) patients (mood disorders, non-AD degenerative dementia, vascular cognitive impairment, alcohol cognitive disorders, temporal epilepsy and hippocampal sclerosis), and 10 (27%) patients had cognitive disorders of undetermined etiology.
Conclusion: AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition. A clinical follow- up is particularly recommended to consider an alternative diagnosis.
Export Options
About this article
Cite this article as:
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers, Current Alzheimer Research 2018; 15 (7) . https://dx.doi.org/10.2174/1567205015666180110113238
DOI https://dx.doi.org/10.2174/1567205015666180110113238 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology <i>In Vitro</i> Antioxidant and Anti-Convulsant Activity of Methanolic Extract of <i>Sarasvata churna</i> Using scPTZ and MES Models
The Natural Products Journal P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry A Salicylic Acid-Based Analogue Discovered from Virtual Screening as a Potent Inhibitor of Human 20α-Hydroxysteroid Dehydrogenase
Medicinal Chemistry Concerns with AED Conversion: Comparison of Patient and Physician Perspectives
Current Neuropharmacology Population Pharmacokinetics of Levetiracetam: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Current Neuropharmacology The Need to Avoid the Routine Use of Episiotomy
Current Women`s Health Reviews Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology The Connections Among Autophagy, Inflammasome and Mitochondria
Current Drug Targets Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design The Role of Inflammation in Epilepsy
Current Pediatric Reviews